Clinical trials: PD-1
Parkinson's Disease
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
This is a Phase I clinical trial of the FDA approved drug Glycerol Phenylbutyrate to see if phenylbutyrate can increase the removal of alpha-synuclein from the brain into the bloodstream.
- Trial name
- NCT02046434
- Testing
- Glycerol Phenylbutyrate
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Melanoma
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma.
- Trial name
- NCT03241927
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nina Bhardwaj
Recurrence, Metastasis
The Clinical Relevance of Immune Cells and CTC in HNSCC Patients
Head and neck squamous cell carcinomas (HNSCCs) are mainly caused by tobacco, alcohol consumption and betel nut chewing and the sixth most common cancer in the world.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- NCT02420600
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Parkinson's Disease (PD), Parkinson's Disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
This clinical study is being conducted to learn more about a new imaging drug called [18F]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD).
- Conditions
- Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- Trial name
- NCT07348250
- Testing
- [18F]MK-0947
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Parkinson Disease
Effect of WB-EMS on Parkinson's Disease
The aim is to establish adequate and suitable protocols for PD patients and to determine the WB-EMS effects on muscle strength, balance, walking, cognitive functions,neurotrophic factors and alpha-synuclein.
- Trial name
- NCT04878679
- Testing
- Strenght training combined with WB-EMS, Cardiovascular training with WB-EMS, Control group
- Where
- Italy
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Università degli studi di Roma Foro Italico
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Multiple System Atrophy, Parkinson's Disease
Prospective Multicenter Registry Study of Multiple System Atrophy in China
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction.
- Conditions
- Multiple System Atrophy, Parkinson's Disease, Atypical Parkinsonism
- Trial name
- MSA Registry S (NCT07644013)
- Where
- China
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Parkinson's Disease (PD), GBA1 Parkinson Disease
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging
The project aims to investigate how abnormal accumulation of alpha synuclein and its interaction with tau influence brain function across the Parkinson's disease (PD) spectrum, with particular focus on individuals carrying GBA1…
- Conditions
- Parkinson's Disease (PD), GBA1 Parkinson Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- SYNchronPD (NCT07474779)
- Testing
- brain imaging, blood draw, Skin biopsy
- Where
- 2 sites in Italy
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Pavia
Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation
SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants
The purpose of this research study is to look at how the proteins and genes in people's skin change when they're exposed to simulated sunlight.
- Trial name
- NCT06177106
- Testing
- Solar Simulated Light
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Hodgkin Lymphoma
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma.
- Trial name
- NCT04026269
- Testing
- MOAP
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Han weidong
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Parkinson's Disease
Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease
In Parkinson's disease (PD), alpha-synuclein accumulation in cutaneous autonomic pilomotor and sudomotor nerve fibers has been linked to autonomic nervous system disturbances even in the early stages of the disease.
- Trial name
- CAPTURE-PD (NCT03043768)
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GWT-TUD GmbH
Phaeohyphomycosis
Efficacy of PD-1 Monoclonal Antibody in the Treatment of Phaeohyphomycosis
The main objective was to evaluate the clinical efficacy of PD-1 inhibitor (PD-1 monoclonal antibody) in the treatment of skin and subcutaneous mucocytosis infection, including the comparison of immune cell groups before and…
- Trial name
- NCT06796231
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-Small Cell Lung Cancer
Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients
Several reports have examined Programmed Death 1 (PD-1) expression on tumor-infiltrating T-cells, and its correlation with prognosis has been discussed.
- Trial name
- NCT02758314
- Testing
- Evaluation of PD-1/PDL-1 expression.
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Hepatocellular Carcinoma
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades. Approximately 70-80% of newly diagnosed HCC patients already have advanced disease.
- Trial name
- NCT04193696
- Testing
- Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Sintilimab, Lung Cancer
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
primary purpose：Observe the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.
- Conditions
- Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
- Trial name
- NCT05400070
- Testing
- Neoadjuvant therapy 1
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Trauma Patients
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality
Unlike neuro-endocrine response to trauma; posttraumatic immune alterations are not easily carried out at bedside. The majority of trials were conducted in the intensive care usually hours to days post injury.
- Trial name
- NCT04233723
- Testing
- peripheral blood samples
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University